Beyaz is claimed to be the first and only oral contraceptive (OC) approved to raise folate levels in women who choose an OC for birth control. In these women, Beyaz raises folate levels for the purpose of reducing the risk of a neural tube defect (NTD) in a pregnancy conceived while taking Beyaz or shortly after discontinuing it. It combines the hormone ingredients in the birth control pill YAZ (drospirenone 3 mg/ ethinyl estradiol 20 mcg) with 451 mcg levomefolate calcium, which is a B vitamin. Manufacturer:Bayer HealthCare Pharmacological Class:Combination oral contraceptive (progestin + estrogen) + folate. Active Ingredient(s):Drospirenone 3mg + ethinyl estradiol (as betadex clathrate) 20micrograms + levomefolate calcium 0.451mg (24 pink tabs); levomefolate calcium 0.451mg (4 light orange tablets). Indication(s):Oral contraception. Premenstrual dysphoric disorder (PMDD) in women who choose an oral contraceptive for contraception. Moderate acne vulgaris in women ≥14 years old who choose an oral contraceptive for contraception. To raise folate levels in women who choose to use an oral contraceptive for contraception. Pharmacology:Combined oral contraceptives reduce the risk of pregnancy primarily by inhibiting ovulation. This product combines drospirenone, an analogue of spironolactone that has both antimineralocorticoid and antiandrogenic activities, with an estrogen plus folate supplementation. Levomefolate calcium 0.451mg (equivalent to folic acid 0.4mg) is included for reducing the risk of neural tube defects in a pregnancy conceived while taking the product or shortly after discontinuing the product. Legal Classification:Rx Adults:1 tablet daily for 28 days; repeat. Take at the same time daily. Use Day 1 or Sunday start for 1st cycle; use backup method for first 7 days. Allow at least 4 weeks postpartum, if not breastfeeding, to begin cycle. Children:Premenarchal: not recommended. Contraindication(s):Renal impairment. Adrenal insufficiency. High risk of arterial or venous thrombotic disease (eg, smokers or migraineurs over age 35, history of DVT or thromboembolism, cerebrovascular or coronary artery disease, thrombogenic valvular disease, atrial fibrillation, subacute bacterial endocarditis, hypercoagulopathies, uncontrolled hypertension, diabetes with vascular disease, headaches with focal neurologic symptoms). Breast or other estrogen or progestin-sensitive neoplasms. Hepatic disease or tumors. Undiagnosed abnormal uterine bleeding. Pregnancy (Cat.X). Warnings/Precautions:Discontinue if thrombotic event, unexplained visual changes, or jaundice occurs, and at least 4 weeks before through 2 weeks after surgery associated with increased risk of thromboembolism. Hyperkalemia or risk thereof. Diabetes. Prediabetes. Uncontrolled dyslipidemias. Pregnancy-related cholestasis. Depression. Evaluate significant changes in headaches, irregular uterine bleeding, amenorrhea. Monitor blood pressure. Nursing mothers: not recommended. Interaction(s):May potentiate drugs that can cause hyperkalemia in chronic use (eg, ACE inhibitors, ARBs, NSAIDs, K+ sparing diuretics, K+ supplementation, heparin, aldosterone blockers) (check serum K+ during 1st cycle). May be antagonized by CPY3A4 or other enzyme inducers (eg, barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John’s wort, topiramate) (use backup contraception). May be affected by protease inhibitors, acetaminophen, ascorbic acid, itraconazole, ketoconazole. May antagonize lamotrigine. May affect laboratory tests (eg, coagulation factors, lipids, glucose tolerance, binding proteins). May need dose adjustment of thyroid hormones. May mask vitamin B12 deficiency (folate). Adverse Reaction(s):Irregular uterine bleeding, headache, nausea, mastodynia, fatigue, irritability, decreased libido, increased weight, fluid retention, mood changes; others (see literature). Notes:Use backup method or restart if 2 or more pink pills are missed (see literature); consider severe nausea/diarrhea as missed pill. Continue folate supplementation if pills are discontinued due to pregnancy. How Supplied:Packs—3 (3x28 day cycles) 近日,美国食品药品监督管理局批准拜耳公司申请的联用避孕药Beyaz片剂上市,该药物是雌激素(戊酸雌二醇)和孕激素(地诺孕素)及叶酸(添加左甲基四氢叶酸钙0.451mg)的联用药物。 左甲基四氢叶酸钙是叶酸代谢物,是产生和维持人体内新细胞的水溶性维生素B,妇女在怀孕分娩期间叶酸缺乏会引起神经管缺陷症(如脊柱裂)。 药理分类: 活性成分(补): 指示(补): 药理作用:
成人: 儿童: 禁忌(补): 警告/注意事项: 互动(补): 如何提供: 最后更新: |
当前位置:药品说明书与价格首页 >> 综合药讯 >> Beyaz复方片剂-在美国获批准上市
Beyaz复方片剂-在美国获批准上市简介:
近日,美国食品药品监督管理局批准拜耳公司申请的联用避孕药Beyaz片剂上市,该药物是雌激素(戊酸雌二醇)和孕激素(地诺孕素)及叶酸(添加左甲基四氢叶酸钙0.451mg)的联用药物。
左甲基四氢叶酸钙是叶酸代 ... 责任编辑:admin
|
最新文章更多推荐文章更多热点文章更多
|